Rein Therapeutics releases scientific presentation on IPF candidate LTI-03

The update also notes an enrolling Phase 2 RENEW trial for LTI-03 in IPF, listed as NCT06968845.

Rein Therapeutics published a scientific presentation outlining its fibrosis pipeline, centered on inhaled IPF candidate LTI-03.

• The deck highlights Phase 1b results: 5 mg and 10 mg doses were tolerated over 14 days, with no treatment-related serious adverse events.
• Exploratory biomarker readouts showed nominal significance in 5 markers at 10 mg and 2 at 5 mg, aligned with preclinical findings.
• The presentation positions LTI-03 as a caveolin-1 scaffolding domain mimic with dual anti-fibrotic, epithelial-protective activity, delivered by dry powder inhaler.